CEP-37440

Known as: ALK-FAK Inhibitor CEP-37440 
An orally available dual kinase inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and focal adhesion kinase (FAK), with… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2009-2016
01220092016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Inflammatory breast cancer (IBC) is an aggressive type of advanced breast cancer with a poor prognosis. We recently found that… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 5
Is this relevant?
2016
2016
Analogues structurally related to anaplastic lymphoma kinase (ALK) inhibitor 1 were optimized for metabolic stability. The… (More)
Is this relevant?
Review
2015
Review
2015
Anaplastic lymphoma kinase 1 (ALK-1) is a member of the insulin receptor tyrosine kinase family. ALK-1 was initially found in… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
Review
2014
Review
2014
The treatment of patients with advanced non-small cell lung cancer (NSCLC) harboring chromosomal rearrangements of anaplastic… (More)
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2009
2009
OBJECTIVE To study focal adhesion kinase (FAK) expression in hypoxia-stressed SMMC-7721 cells and the role of FAK expression in… (More)
Is this relevant?